Mumbai, April 30 (IANS). Dr. Lal PathLabs on Thursday released the results for the fourth quarter of the financial year 2025-26. The company said that its net profit has declined by 15.2 percent in the quarter ended March 31.
In a stock exchange filing, the company said that its net profit in the fourth quarter was Rs 131.3 crore, which was Rs 154.8 crore in the same quarter of the last financial year.
Despite the decline in profit, there was a good increase in the company’s revenue, which increased by 16.6 percent year-on-year to Rs 702.7 crore, which was earlier Rs 602.6 crore. This increase was due to continuous demand and more tests.
The company recorded marginal growth in its operating performance, with EBITDA growing 11 per cent to Rs 186.8 crore from Rs 169 crore last year.
However, the company saw pressure on its margins in this quarter and the EBITDA margin declined to 26.6 percent, which was 28 percent last year.
For shareholders, the company has recommended a final dividend of Rs 4 per share (40 percent) at Rs 10 face value for FY 2026.
This dividend will be given after getting approval in the upcoming Annual General Meeting (AGM). The record date for this has been fixed as 26 June 2026.
Following the results, the company’s shares closed 1.7 per cent lower at Rs 1,374 on the NSE on April 30.
The company’s shares have fallen 2.90 percent in the last 5 days. The stock has given a positive return of 3.81 percent in the last one month.
The company’s stock has fallen 12.36 percent in the last 6 months, while so far this year the stock has given a negative return of 8.99 percent to investors.
–IANS
DBP
